Assessment, types, and etiologies of vision loss in primary care settings

Ahmed Thabit Al Nahdi, Abdulaziz Ahmad Alobaid, Abdullah Khalid Alajmi, Abdullah Saleh Al Majed, Ali Abdulhaq Alkhars, Manal Amer Alsayyar, Husain Amer Althani, Abdulaziz Jamal Almansour, Khaled Ali Alsaadi, Norah Abdullah Aljaloud, Saga Khaled Alwabel


Studies indicate the vital roles that family physicians play in the diagnosis and assessment of vision loss in the primary care settings. In ddition, family physicians give proper advice to patients and refer them to other departments for adequate screening and management of any associated comorbidities. In this literature review, we have discussed the types, etiologies, and assessment of each cause of vision loss in primary care settings. The most commonly reported etiologies include age-related macular degeneration (AMD), diabetic retinopathy, glaucomas, cataracts, and errors of refraction. The main types of vision loss usually include peripheral vision loss, central vision loss, blurred or patchy vision, and vision loss that is usually associated with a physical disability or an acquired brain injury. Providing adequate management and routine screening for the patients that are affected by the aforementioned etiologies can significantly enhance their outcomes and reduce the risk of vision loss. Providing educational campaigns about the importance of treatment compliance and routine screening should also be conducted to increase awareness and enhance the outcomes in the primary care settings.


Vision loss, Etiology, Type, Management, AMDs, Cataract, Glaucoma

Full Text:



Pelletier AL, Thomas J, Shaw FR. Vision loss in older persons. Ame family physician. 2009;79(11):963-70.

Varma R, Vajaranant TS, Burkemper B, et al. Visual Impairment and Blindness in Adults in the United States: Demographic and Geographic Variations From 2015 to 2050. JAMA ophthalmol. 2016;134(7):802-9.

Steinmetz JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2021;9(2):e144-60.

Geruschat D, Dagnelie G. Low vision: Types of vision loss and common effects on activities of daily life. In Assistive Technology for Blindness and Low Vision, 1st edi. 2012:59-80.

Cui Y, Zhang L, Zhang M. Prevalence and causes of low vision and blindness in a Chinese population with type 2 diabetes: the Dongguan Eye Study. Scientific Rep. 2017;7(1):11195.

Addo EK, Akuffo KO, Sewpaul R. Prevalence and associated factors of vision loss in the South African National Health and Nutrition Examination Survey (SANHANES-1). BMC Ophthalmol. 2021;21(1):1.

Flaxman SR, Bourne RRA, Resnikoff S. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Global health. 2017;5(12):e1221-34.

Feder RS, Olsen TW, Prum BE, Jr. Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern® Guidelines. Ophthalmology. 2016;123(1):P209-36.

Lee DJ, Kumar N, Feuer WJ. Dilated eye examination screening guideline compliance among patients with diabetes without a diabetic retinopathy diagnosis: the role of geographic access. BMJ open diabetes research & care. 2014;2(1):e000031.

Siu AL, Bibbins-Domingo K, Grossman DC. Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement. Jama. 2016;315(9):908-14.

Quigley HA. Glaucoma. Lancet (London, England). 2011;377(9774):1367-77.

Moyer VA. Screening for glaucoma: U.S. Preventive Services Task Force Recommendation Statement. Ann internal med. 2013;159(7):484-9.

Kass MA, Heuer DK, Higginbotham EJ. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch ophthalmol. 2002;120(6):701-13.

Son PT, Reda A, Viet DC. Exchange transfusion in the management of critical pertussis in young infants: a case series. Vox Sanguinis. 2021.

Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Survey ophthalmol. 2008;53(1):S57-68.

Waterman H, Evans JR, Gray TA, Henson D, Harper R. Interventions for improving adherence to ocular hypotensive therapy. Cochrane database of systematic reviews. 2013(4):Cd006132.

Samples JR, Singh K, Lin SC. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011;118(11):2296-302.

Riaz Y, Mehta JS, Wormald R. Surgical interventions for age-related cataract. Cochrane database of systematic reviews. 2006;2006(4):Cd001323.

Schein OD, Katz J, Bass EB. The value of routine preoperative medical testing before cataract surgery. Study of Medical Testing for Cataract Surgery. N Eng j med. 2000;342(3):168-75.

Keay L, Lindsley K, Tielsch J, Katz J, Schein O. Routine preoperative medical testing for cataract surgery. Cochrane database systematic reviews. 2019;1(1):Cd007293.

Schein O, Katz J, Bass E. The value of routine preoperative medical testing before cataract surgery. Study of Medical Testing Center for Cataract Surgery. Evidence-based Eye Care. 2000;1.

Neel ST. A cost-minimization analysis comparing immediate sequential cataract surgery and delayed sequential cataract surgery from the payer, patient, and societal perspectives in the United States. JAMA ophthalmol. 2014;132(11):1282-8.

Thieu H, Bach Dat B, Nam NH. Antibiotic resistance of Helicobacter pylori infection in a children's hospital in Vietnam: prevalence and associated factors. Minerva medica. 2020;111(5):498-501.

Galor A, Lee DJ. Effects of smoking on ocular health. Current opinion ophthalmol. 2011;22(6):477-82.

Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Survey ophthalmol. 1998;42(6):535-47.

Roberts JE. Ultraviolet radiation as a risk factor for cataract and macular degeneration. Eye contact lens. 2011;37(4):246-9.

Flaxel CJ, Adelman RA, Bailey ST. Diabetic Retinopathy Preferred Practice Pattern. Ophthalmology. 2020;127(1):P66-145.

Kirkman MS, Briscoe VJ, Clark N. Diabetes in older adults. Diabetes care. 2012;35(12):2650-64.

Kirkman MS, Briscoe VJ, Clark N. Diabetes in older adults: consensus report. J Am Geriatrics Society. 2012;60(12):2342.

Stratton IM, Kohner EM, Aldington SJ. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156-63.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng j med. 2008;359(15):1577-89.

Chew EY, Ambrosius WT, Davis MD. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Eng j med. 2010;363(3):233-44.

Gerstein HC, Miller ME, Genuth S. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Eng j med. 2011;364(9):818-28.

Keech AC, Mitchell P, Summanen PA. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687-97.

Wong TY, Simó R, Mitchell P. Fenofibrate-a potential systemic treatment for diabetic retinopathy? Am j ophthalmol. 2012;154(1):6-12.

Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane database systematic reviews. 2014;2014(11):Cd011234.

Martinez‐Zapata MJ, Martí‐Carvajal AJ, Solà I. Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Systematic Reviews. 2014;11.

Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye. 2014;28(5):510-20.

Wells JA, Glassman AR, Ayala AR. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The N Eng j med. 2015;372(13):1193-203.

Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane database systematic reviews. 2014(10):Cd007419.

Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane database systematic reviews. 2008(1):Cd005656.

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch ophthalmol. 2001;119(10):1417-36.

Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane database systematic reviews. 2017;7(7):Cd000253.

Chew EY, Clemons T, SanGiovanni JP. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119(11):2282-9.

Tufail A, Patel PJ, Egan C. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMI. 2010;340:c2459.

Moja L, Lucenteforte E, Kwag KH. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane database systematic reviews. 2014;9(9):Cd011230.

Goldberg RA, Flynn HW, Jr., Isom RF, Miller D, Gonzalez S. An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am j ophthalmol. 2012;153(2):204-8.